Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Qiagen agrees to distribute Whatman FTA product range and FTA-based kits

QIAGEN : 22 May, 2007  (New Product)
Whatman and Qiagen have agreed a non-exclusive distribution partnership that provides Qiagen with the right to market and sell Whatman FTA and and FTA-based kits to all Qiagen's target market sectors.
The markets include life science research, molecular diagnostics and applied testing.

The agreement provides Qiagen with distribution rights for existing Whatman FTA products as well as customised products.

As part of the agreement, Qiagen will pay Whatman an initial fee that grants Qiagen non-exclusive distribution rights.

In addition, royalties will be paid by Qiagen to Whatman on the sale of all products that incorporate the use of FTA.

Whatman's FTA technology has created a standard in the field of collection, storage and release of DNA and has a wide range of potential applications including forensics, pharmacogenomics, biobanking and genomics research.

Whatman's FTA products are composed of a chemically treated matrix that lyses cells and immobilises nucleic acids on contact, enabling scientists to collect, transport, archive and release nucleic acids at room temperature using an easy to perform protocol.

Whatman's FTA technology is highly synergistic with Qiagen's sample preparation product portfolio.

The addition of FTA has the potential to broaden Qiagen's value proposition for Qiagen's customers in key markets.

Nucleic acids stored on FTA and purified with Qiagen's sample preparation products are well suited for downstream applications such as Qiagen's PCR-based genotyping, molecular testing products and comparative genomic studies.

FTA has also been shown to be compatible with Qiagen's whole genome amplification technology (WGA) for DNA replication currently used in many biobanking applications.

'Whatman is a well established leader in paper-based nucleic acid storage solutions in fields such as forensics, agricultural and environmental ID where easy to use technologies and long term stability are important for customers', said Peer M Schatz, Qiagen's chief executive officer.

'This is an important and synergistic addition to Qiagen's product offering in areas such as molecular diagnostics, pharmacogenomics, and biobanking'.

'We believe that the combination of FTA-technologies and Qiagen technologies allows a very appealing, complete and synchronised workflow for our and Whatman's customers'.

'We are delighted to announce this distribution agreement with Qiagen.
Qiagen's market and technology leadership in genomics research makes it an ideal partner for our FTA technology in this market', said Kieran Murphy, Whatman's CEO.

'This agreement strengthens our reach into valuable segments and will help us realise the potential of this breakthrough DNA collection and storage technology by expanding market access for FTA products through Qiagen's established presence in the laboratory and pharmaceutical sectors'.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo